文献速递肾小球疾病

肠道微生物组作为IgA肾病潜在治疗靶点

The gut microbiome as a potential therapeutic target in IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

IgA肾病是最常见的原发性肾小球肾炎和肾衰竭重要原因,治疗选择有限。其病理生理尚不明确,但遗传、表观遗传和环境因素起重要作用,且有力证据表明肠道微生物组与IgA肾病发生相关。本综述探讨微生物组与IgA肾病发病机制的关系及其作为未来治疗干预靶点的潜力。

要点

  • 肠道微生物组与IgA肾病发生相关
  • IgA肾病治疗选择有限
  • 微生物组可能成为未来治疗靶点

核心结论

  • 肠道微生物组与IgA肾病发生相关,可能作为未来治疗干预的靶点

研究设计与样本

  • 综述,探讨微生物组与IgA肾病发病机制的关系及其治疗靶点潜力

主要发现

  • 遗传、表观遗传和环境因素在IgA肾病中起重要作用
  • 有力证据表明肠道微生物组与IgA肾病发生相关

临床怎么用

  • 肠道微生物组可能作为IgA肾病未来治疗干预的潜在靶点

局限性

  • IgA肾病病理生理尚不明确

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis and a leading cause of kidney failure, with limited treatment options available. The pathophysiology of IgAN remains unclear; however, recent studies suggest that genetic, epigenetic and environmental factors play significant roles. There is also strong evidence linking the gut microbiome to the development of IgAN. In this review, we will examine the relationship between the microbiome and the pathogenesis of IgAN, as well as its potential as a target for future therapeutic interventions.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Pereira IM, Pereira M, Lopes JA, et al. The gut microbiome as a potential therapeutic target in IgA nephropathy. Nephrol Dial Transplant. 2025. PMID: 39663206. doi:10.1093/ndt/gfae274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。